At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
In Brief
A Phase 2 clinical trial evaluating Lutetium [177Lu] oxodotreotide/dotatate for Gastroenteropancreatic Neuroendocrine Tumors and 2 related conditions. Active but no longer recruiting, targeting 11 participants across 7 sites in 5 countries.
Detailed Summary
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Study Details
Timeline
Interventions
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)